Business Context and Reporting Period
The provided filing is Reneo Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 23, 2022. The request metadata identifies Onkure Therapeutics, Inc., but the filing text identifies Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM); this company-name discrepancy should be verified.
Reneo is a clinical-stage pharmaceutical company developing REN001, an oral selective PPARδ agonist for rare genetic mitochondrial diseases, primarily primary mitochondrial myopathy (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). The company had no approved products and generated no product revenue.
Financial Metrics
| Metric | 2021 | 2020 | Change / Comment |
|---|---|---|---|
| Revenue | $0 | $0 | No product sales |
| Research and development expense | $28.2 million | $15.9 million | Increased $12.2 million |
| General and administrative expense | $11.6 million | $3.6 million | Increased $8.0 million |
| Total operating expenses | $39.8 million | $19.6 million | Increased $20.3 million |
| Net loss | $39.8 million | $19.5 million | Loss more than doubled |
| Net loss per share | $2.19 | $9.60 | Per-share comparison affected by the IPO and share-count increase |
| Cash used in operating activities | $38.0 million | $18.5 million | Higher spending reflected clinical development |
| Cash, cash equivalents and short-term investments | $147.7 million | $53.6 million cash | Liquidity increased following financing |
| Accumulated deficit | $84.7 million | $45.0 million | Increased with continuing losses |
Cash and cash equivalents were $124.7 million and short-term investments were $23.0 million at December 31, 2021. Total liabilities were $6.8 million. The filing does not identify material debt; reported liabilities primarily consisted of accounts payable, accrued expenses, deferred rent and a performance-award liability.
Operating margins and profitability margins were not meaningful because the company had no revenue. Stock-based compensation was $3.9 million in 2021, compared with $0.4 million in 2020.
Material Changes Versus the Prior Comparable Period
- R&D spending rose primarily because of increased clinical and manufacturing activity for REN001, higher personnel costs and a $2.0 million development milestone paid to vTv Therapeutics in July 2021.
- G&A spending increased because of the April 2021 initial public offering, expanded personnel, higher insurance premiums and increased public-company professional costs.
- Reneo completed its IPO in April 2021, selling 6.25 million shares at $15.00 per share. Net IPO proceeds were approximately $84.6 million. Convertible preferred stock converted into common stock at the IPO.
- Financing cash inflows totaled $132.4 million in 2021, including approximately $47.2 million from Series B preferred stock and $84.6 million from the IPO.
- Net cash used in investing activities was $23.4 million, primarily reflecting purchases of short-term investments, compared with $7.4 million of investing cash inflows in 2020.
- The first patient in the global Phase 2b STRIDE study for PMM was dosed in July 2021. Enrollment was expected to finish by year-end 2022, with results expected in 2023.
Guidance, Outlook, Risks and Unusual Items
Management expected cash, cash equivalents and short-term investments at December 31, 2021 to fund planned operations into 2024. The company also stated that it will require substantial additional capital and may pursue equity or debt financing, collaborations, strategic alliances or licensing arrangements.
- REN001 is the company’s only product candidate, creating substantial single-asset risk.
- The STRIDE Phase 2b study is randomized, double-blind and placebo-controlled, with approximately 200 adult PMM patients and a primary endpoint based on change in the 12-minute walk test.
- Results from the LC-FAOD Phase 1b study and the FORWARD natural-history study were expected in the second quarter of 2022.
- The company discontinued plans for a Phase 2 McArdle disease study after Phase 1b data showed no corresponding changes in heart rate, fatigue, pain or other symptoms despite improvements in walking distance and fat oxidation.
- Reneo had orphan-drug designations for REN001 in PMM and LC-FAOD in the United States and for certain related indications in Europe. It also reported Fast Track designation for PMM.
- Two-year carcinogenicity studies in rats and mice were ongoing, with results expected in 2023. The filing notes that PPAR agonists have previously raised liver, cardiac and carcinogenicity concerns, although no drug-related serious adverse events had been reported in Reneo’s REN001 trials to date.
- COVID-19 caused early closure of the PMM Phase 1b study and previously paused enrollment in other studies. Future effects on enrollment, trial sites, CROs, manufacturing and regulatory timelines remained uncertain.
- The company relies on third parties for clinical trials and manufacturing, including single-source suppliers for clinical API and drug product. It had no long-term manufacturing agreements for REN001.
- The vTv license requires up to $64.5 million of development and regulatory milestones, up to $30.0 million of sales milestones and tiered royalties ranging from mid-single-digit to low-teen percentages of annual net sales.
- A $7.5 million performance award for the chief executive officer was subject to market-value or change-in-control conditions. A $0.4 million liability was recorded at year-end 2021.
- The company reported no pending legal proceedings expected to have a material adverse effect and no income-tax provision for 2021. Deferred tax assets were fully offset by a valuation allowance.
Most Important Facts for Investors to Verify
- Confirm that the filing belongs to Reneo Pharmaceuticals, Inc., not Onkure Therapeutics, Inc.
- Verify the company’s liquidity runway and the assumptions supporting management’s expectation of funding into 2024.
- Track STRIDE enrollment, protocol execution, endpoint acceptance by regulators and expected 2023 results.
- Assess whether early-stage, open-label efficacy signals for PMM and LC-FAOD are supported by controlled, adequately powered studies.
- Review carcinogenicity-study results and any emerging safety findings for REN001.
- Monitor additional financing needs, potential dilution and the terms of any future equity, debt or partnership transactions.
- Review vTv milestone, royalty and license-termination obligations, as well as patent expiration dates and exclusivity assumptions.
- Evaluate manufacturing capacity, single-source supply exposure and the effect of COVID-19 or other disruptions on clinical timelines.